Co-Diagnostics (NASDAQ:CODX) & Intelligent Bio Solutions (NASDAQ:INBS) Head to Head Review

Co-Diagnostics (NASDAQ:CODX) and Intelligent Bio Solutions (NASDAQ:INBS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Earnings & Valuation

This table compares Co-Diagnostics and Intelligent Bio Solutions”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Co-Diagnostics	$7.32 million	2.44	-$35.33 million	($1.38)	-0.41
Intelligent Bio Solutions	$3.03 million	5.41	-$10.16 million	N/A	N/A

Intelligent Bio Solutions has lower revenue, but higher earnings than Co-Diagnostics.

Profitability

This table compares Co-Diagnostics and Intelligent Bio Solutions’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Co-Diagnostics	-563.93%	-54.94%	-49.28%
Intelligent Bio Solutions	-323.79%	-146.03%	-83.62%

Insider and Institutional Ownership

15.0% of Co-Diagnostics shares are owned by institutional investors. Comparatively, 33.0% of Intelligent Bio Solutions shares are owned by institutional investors. 6.1% of Co-Diagnostics shares are owned by insiders. Comparatively, 0.3% of Intelligent Bio Solutions shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Co-Diagnostics and Intelligent Bio Solutions, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Co-Diagnostics	0	1	0	0	2.00
Intelligent Bio Solutions	0	0	0	0	0.00

Co-Diagnostics currently has a consensus target price of $1.50, indicating a potential upside of 167.86%. Given Co-Diagnostics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Co-Diagnostics is more favorable than Intelligent Bio Solutions.

Risk & Volatility

Co-Diagnostics has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500. Comparatively, Intelligent Bio Solutions has a beta of 4.63, meaning that its stock price is 363% more volatile than the S&P 500.

Summary

Co-Diagnostics beats Intelligent Bio Solutions on 6 of the 11 factors compared between the two stocks.

About Co-Diagnostics

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

About Intelligent Bio Solutions

Intelligent Bio Solutions Inc., a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.